Iohexol

Sickle Cell Disease

University Hospital, ToursSmall moleculeN/AActive

D

28/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 65/ 100

Competitive context

132 Active assets in the Sickle Cell Disease cohort.

Asset / Sponsor	Phase	Rating
Glutamine Ain Shams University	Phase 4	BBB
Hydroxyurea St. Jude Children's Research Hospital	Phase 4	BB
Crizanlizumab Novartis Pharmaceuticals	Phase 4	BB
Nivestim St. Jude Children's Research Hospital	Phase 4	BB
Magnesium Metallicum Medical College of Wisconsin	Phase 3	BB

View all 50 →

Same molecule, other indications

Iohexol is also rated in:

diabetic kidney diseaseActive

CCC

Indicative · Phase 1/2

52 / 100

diabetes mellitusDormant

CCC

Indicative · Phase 1/2

50 / 100

type 2 diabetes mellitusActive

CCC

Indicative · Phase 1/2

50 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.